EchoStar is experiencing a surge after President Trump urged a deal with the FCC over its wireless licenses. Meanwhile, US Steel is rallying due to Nippon Steel's $14.1 billion acquisition approval, which includes significant government oversight. On a darker note, Sarpeta Therapeutics faces scrutiny after a second patient died during its gene therapy trials, raising concerns about FDA decisions. The podcast also touches on Victoria's Secret navigating pressures from activist investors, illustrating the volatile landscape of the stock market.
04:42
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
EchoStar Spectrum Dispute Insight
EchoStar faces pressure from the FCC to either build a wireless network or relinquish spectrum rights after heavy debt and no network buildout.
President Trump intervened urging the FCC to ease restrictions, offering hope for a resolution with government support.
insights INSIGHT
US Steel Acquisition Insights
Nippon Steel gained US approval to acquire US Steel for $14.1 billion with conditions including a "golden share" granting US government decision influence.
The deal marks a major overseas investment with government oversight and plans for significant investment.
insights INSIGHT
Sarepta Gene Therapy Concerns
Sarepta Therapeutics' gene therapy faces intense scrutiny after two patients died of acute liver failure, severely impacting its stock.
FDA approval is questioned due to lack of data showing the therapy slows overall disease progression.
Get the Snipd Podcast app to discover more snips from this episode
On this episode of Stock Movers: - EchoStar (SATS) is soaring this morning as President Trump urges the company to make a deal with the FCC for its wireless spectrum licenses. The president met with EchoStar Chairman Charlie Ergen and Carr at the White House, encouraging them to work together and reach a deal. The FCC is investigating whether EchoStar is meeting obligations for its wireless and satellite spectrum rights, and the company has been skipping bond coupon payments and considering filing for bankruptcy. - US Steel (X) is rallying today as Nippon Steel secured approval from President Trump to purchase United States Steel Corp. for $14.1 billion, its biggest ever overseas bet. The deal comes with significant concessions to the US government, including a "golden share" that gives Washington a say in major decisions and control over some board seats, and a promise to invest $14 billion over the coming years. - Roche (RHHBY) is slightly down, but its partner Sarpeta Therapeutics (SRPT) is plunging on news that a second patient has died of acute liver failure while being treated with Sarepta Therapeutics Inc.'s gene therapy for a rare muscle disorder, following a similar death three months prior. The development has cast a pall over Sarpeta's most important drug and will intensify scrutiny on the FDA over its decision to approve it, despite a lack of data showing it slows overall progression of the disease. - Victoria's Secret (VSCO) is up on news Barington Capital Group has built a stake in Victoria's Secret & Co. and plans to urge changes to its board and strategy. The company is under pressure to grow sales amid new competition, and its shares have declined 56% this year through Friday. The company has faced challenges, including tariffs, weakening consumer spending, and a security incident that took its e-commerce operation offline, affecting its goal to regain dominance in bras.
Stock Movers